ACE-031 (ActRIIB-Fc): Decoy Receptor Design, Ligand Promiscuity and Research Context

ACE-031 works as a soluble decoy. It consists of the extracellular, ligand-binding part of human activin receptor type IIB fused to the Fc portion of human IgG1, and it is expressed as a homodimer held together by disulfide bonds. Circulating myostatin and related TGF-β superfamily ligands are caught by this decoy before they can bind the receptor anchored in the cell membrane. The molecule was developed by Acceleron Pharma and appears in the literature as ActRIIB-Fc or ramatercept. It reached Phase 2 before development stopped in 2013 — background that matters when reading any paper that uses it.

We offer ACE-031 as a freeze-dried recombinant protein, 1 mg per vial, within the IGF and muscle peptides range. It is sold strictly for laboratory research.

Defining ACE-031

Strictly speaking, ACE-031 is not a peptide but a two-part fusion protein. The first part is the ectodomain of ActRIIB, one of the two type II activin receptors that initiate SMAD2/3 signalling in skeletal muscle. The second is the Fc fragment of human IgG1, a standard building block in protein engineering that does two jobs at once: it makes the construct dimerise, giving it a pair of ligand-binding arms, and it uses recycling by the neonatal Fc receptor to stretch circulating half-life from hours into days.

The result combines the ligand selectivity of a receptor with the long circulation of an antibody, and it cannot transmit any signal itself — the classic ligand-trap design. Because it is a glycosylated dimer, it runs well above the 70 kDa mark on SDS-PAGE, which is convenient as a quick identity check.

Origin and design

The idea came directly out of genetics of the myostatin pathway. Myostatin (GDF-8) restrains how much skeletal muscle an animal builds, and loss-of-function variants — reported in livestock, in mice and in people — produce strikingly enlarged musculature. Because myostatin transmits its signal through ActRIIB, filling the extracellular space with soluble copies of that receptor diverts the ligand away from the receptors on the cell surface.

The key design problem lies in everything else ActRIIB binds. Its natural partners include activin A and activin B, GDF-11 (a close relative of myostatin involved in development) and several bone morphogenetic proteins, notably BMP9 and BMP10. A soluble ActRIIB decoy therefore mops up much more than myostatin, and later molecules in this class were engineered mainly to narrow that binding range.

Proposed mechanism

The mechanism is competitive sequestration of ligand before it reaches the cell. With the ligand bound up by the decoy, ActRIIB on the muscle cell stays empty, the type I partner (ALK4/ALK5) is not recruited or phosphorylated, and less SMAD2/3 signal reaches the nucleus. In muscle models this is described as releasing the brake on growth-related gene programmes and shifting signalling toward protein synthesis via the Akt/mTOR pathway.

Because it binds so broadly, two further mechanistic effects follow. Animal studies saw changes in bone as well as muscle, consistent with what activins and BMPs do in bone turnover. More significantly, BMP9/BMP10 signalling through ALK1 on endothelial cells helps maintain blood-vessel integrity, and most authors link the vascular observations that ended ACE-031's clinical programme to that pathway rather than to muscle signalling. In practice, researchers should describe ACE-031 as a broad-spectrum ActRIIB ligand trap rather than a myostatin-selective tool, and state that clearly when interpreting results.

Consider the three options side by side. Follistatin-344 binds the ligands themselves; the GDF-8 / myostatin propeptide is myostatin's own natural inhibitor and the most selective of the group; ACE-031 blocks the pathway where ligand meets receptor. Which one to use is a real design decision about the point in the pathway you want to block.

Research to date

Muscle and bone models

In rodents, soluble ActRIIB-Fc constructs produced substantial increases in lean mass and muscle fibre size, including in models of muscular dystrophy and cachexia; other studies found increased bone mineral density. Those findings led to the clinical programme.

Phase 1 pharmacology

In a Phase 1 study of healthy postmenopausal women, one dose was reported to raise lean mass and to shift markers of fat mass and bone formation, and the pharmacokinetic profile matched what an Fc-extended protein would be expected to show. This remains the clearest published evidence that the mechanism reaches its target in people.

Duchenne studies and the halt

The Phase 2 study in boys with Duchenne muscular dystrophy was stopped in 2013. The reason given was not a lack of effect on muscle but findings elsewhere — epistaxis, gum bleeding and telangiectasia-like dilation of small surface vessels — which fit a disturbance of BMP9/BMP10-ALK1 signalling in blood vessels. ACE-031 was never taken forward again, and research use should be described with that history in mind.

Later compounds

The drug class moved on. Later ActRII-targeting agents were more selective — ligand traps with a narrower binding profile and monoclonal antibodies directed at the receptor — and several have gained approval in blood disorders and pulmonary disease. ACE-031 is best understood as the first-generation compound whose limitations informed those successors.

Format and size

At the nanomolar concentrations a protein like this is used at, 1 mg amounts to a large molar supply, so labs routinely finish aliquoting the whole vial on the day it is first reconstituted. For sourcing considerations, see our ACE-031 buying guide.

Reconstitution and storage in the lab

Nothing else in a peptide catalogue is as fragile as an Fc-fusion protein, and it should be treated accordingly. Introduce sterile or bacteriostatic water gently against the side of the vial and then leave it alone. Vortexing or shaking a large glycoprotein generates shear aggregates, and no amount of further mixing reverses that. If the liquid is still hazy once everything has dissolved, you are looking at aggregation — treat it as a failed vial, not as under-mixing.

The arithmetic is easy — 1 mg in 1 mL gives 1 mg/mL, so 0.1 mL contains 100 mcg — but assays run at far lower concentrations, and at those levels most material is lost by sticking to plastic and glass. Dilute stocks are routinely supplemented with a carrier such as 0.1% BSA, and low-retention tubes help. See our reconstitution guide for the general procedure.

Keep unopened freeze-dried vials at −20 °C, sealed, dark and dry. Reconstituted protein can be used at 2-8 °C for immediate work; otherwise divide it into aliquots and freeze them, because putting an Fc fusion through repeated freezing and thawing reliably generates aggregates and loses activity. For general principles see how to store peptides.

Purity and reading the COA

The certificate for a fusion protein looks different from a peptide certificate, and the informative sections are not the HPLC ones. SDS-PAGE should be shown under reducing and non-reducing conditions, with monomer and disulfide-bonded dimer bands at the right sizes; if the non-reducing lane is mostly monomer, the dimer did not form properly. Size-exclusion data, where provided, quantify high-molecular-weight aggregates — the commonest reason a vial turns out inactive. The expression host and glycosylation state should be stated, and endotoxin levels are important for any cell work. An activity figure from a binding or reporter assay is more informative than any purity number. Our guide to reading a certificate of analysis shows how the sections relate.

Regulatory position

No regulator anywhere has authorised ACE-031 as a medicine. Its clinical programme stopped in 2013 and was never restarted, so there is neither a reference-listed product nor approved labelling for it. Compounds that act on the myostatin pathway are prohibited in sport under anti-doping rules.

Related molecules and further reading

Besides ACE-031, our catalogue includes two other tools for this pathway: Follistatin-344, a ligand trap with wide specificity, and the GDF-8 / myostatin propeptide, the most selective for its ligand. The peptides for muscle growth research overview explains how the different muscle research families fit together.

Matching catalogue section: IGF & Muscle Peptides